Arkolith/Insider Trading/KYTX/Form 4

Gilead Sciences, Inc.

10% OwnerKyverna Therapeutics, Inc. (KYTX) · full profile →Form 4 · filed Feb 13, 2024
Net Buying
Open-Market Buys
$20.0M
Open-Market Sells
$0
Net Open-Market Flow
$20.0M
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 12, 2024Conversion(C)3.2M——3.2M
Feb 12, 2024Buy(P)910K$22.00$20.0M4.1M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 12, 2024Conversion(C)6.9M—$00
Feb 12, 2024Conversion(C)7.7M—$00

Transaction Codes

C
Conversion of a derivative
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001062993-24-003026) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML